

Enzo Ierardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089046/publications.pdf>

Version: 2024-02-01

239
papers

7,378
citations

57631

44
h-index

82410

72
g-index

243
all docs

243
docs citations

243
times ranked

6532
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review: endoscopic dilatation in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1457-1464.	1.9	266
2	Effects of <i>Helicobacter pylori</i> Eradication on Early Stage Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 105-110.	2.4	256
3	High eradication rates of <i>Helicobacter pylori</i> with a new sequential treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 719-726.	1.9	199
4	Worldwide <i>H. pylori</i> antibiotic resistance: a systematic review. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2010, 19, 409-14.	0.5	199
5	Clarithromycin-Resistant Genotypes and Eradication of <i>Helicobacter pylori</i> . <i>Annals of Internal Medicine</i> , 2006, 144, 94.	2.0	170
6	<i>Lactobacillus reuteri</i> therapy to reduce side-effects during anti- <i>Helicobacter pylori</i> treatment in children: a randomized placebo controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1461-1468.	1.9	155
7	Clarithromycin-Resistant Genotypes and Eradication of <i>Helicobacter Pylori</i> . <i>Journal of Pediatrics</i> , 2010, 157, 228-232.	0.9	147
8	Inhibition of <i>Helicobacter pylori</i> Infection in Humans by <i>Lactobacillus reuteri</i> ATCC 55730 and Effect on Eradication Therapy: A Pilot Study. <i>Helicobacter</i> , 2008, 13, 127-134.	1.6	135
9	Improved Efficacy of 10-Day Sequential Treatment for <i>Helicobacter pylori</i> Eradication in Children: A Randomized Trial. <i>Gastroenterology</i> , 2005, 129, 1414-1419.	0.6	134
10	Curcumin and Colorectal Cancer: From Basic to Clinical Evidences. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2364.	1.8	133
11	Vertical Transmission of Hepatitis C Virus in a Cohort of 2,447 HIV-Seronegative Pregnant Women: A 24-Month Prospective Study. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 570-575.	0.9	118
12	Mechanisms of <i>Helicobacter pylori</i> antibiotic resistance: An updated appraisal. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2011, 2, 35.	0.5	113
13	A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 45-49.	1.9	106
14	Guidelines for the management of <i>Helicobacter pylori</i> infection in Italy: The III Working Group Consensus Report 2015. <i>Digestive and Liver Disease</i> , 2015, 47, 903-912.	0.4	106
15	Phenotypic and genotypic <i>Helicobacter pylori</i> clarithromycin resistance and therapeutic outcome: benefits and limits. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 327-332.	1.3	97
16	How antibiotic resistances could change <i>Helicobacter pylori</i> treatment: A matter of geography?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8168.	1.4	94
17	<i>Lactobacillus reuteri</i> Strain Combination In <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 407-413.	1.1	93
18	A third-line levofloxacin-based rescue therapy for <i>Helicobacter pylori</i> eradication. <i>Digestive and Liver Disease</i> , 2003, 35, 232-236.	0.4	92

#	ARTICLE	IF	CITATIONS
19	Sequential treatment for <i>Helicobacter pylori</i> does not share the risk factors of triple therapy failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 407-414.	1.9	90
20	High rate of <i>Helicobacter pylori</i> eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1419-1424.	1.9	90
21	Prevalence of primary clarithromycin resistance in <i>Helicobacter pylori</i> strains over a 15 year period in Italy. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 783-785.	1.3	90
22	The Influence of <i>Lactobacillus brevis</i> on Ornithine Decarboxylase Activity and Polyamine Profiles in <i>Helicobacter pylori</i> -Infected Gastric Mucosa. <i>Helicobacter</i> , 2004, 9, 165-172.	1.6	87
23	Eradication Therapy for <i>Helicobacter pylori</i> in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1932-1937.	0.2	84
24	<i>Anisakis pegreffii</i> Etiological Agent of Gastric Infections in Two Italian Women. <i>Foodborne Pathogens and Disease</i> , 2009, 6, 1157-1159.	0.8	83
25	Sequential, concomitant and hybrid first-line therapies for <i>Helicobacter pylori</i> eradication: a prospective randomized study. <i>Journal of Medical Microbiology</i> , 2014, 63, 748-752.	0.7	80
26	Probiotic monotherapy and <i>Helicobacter pylori</i> eradication: A systematic review with pooled-data analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 139-149.	1.4	78
27	<i>Escherichia coli</i> Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 499-505.	0.5	77
28	Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 371-377.	1.9	71
29	The prolongation of triple therapy for <i>Helicobacter pylori</i> does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. <i>Digestive and Liver Disease</i> , 2004, 36, 322-326.	0.4	66
30	Primary clarithromycin resistance in Italy assessed on <i>Helicobacter pylori</i> DNA sequences by TaqMan real-time polymerase chain reaction. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 429-435.	1.9	63
31	Endothelial function and cardiovascular risk in active inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e427-e433.	0.6	62
32	Reflux Symptoms in Professional Opera Choristers. <i>Gastroenterology</i> , 2007, 132, 890-898.	0.6	60
33	Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm. <i>World Journal of Gastroenterology</i> , 2018, 24, 1521-1530.	1.4	59
34	Tumour necrosis factor α downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. <i>Gut</i> , 2006, 55, 589-590.	6.1	58
35	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1589-1596.	0.9	58
36	Two new treatment regimens for <i>Helicobacter pylori</i> eradication: a randomised study. <i>Digestive and Liver Disease</i> , 2001, 33, 676-679.	0.4	55

#	ARTICLE	IF	CITATIONS
37	Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 550.	0.5	54
38	The augmenter of liver regeneration induces mitochondrial gene expression in rat liver and enhances oxidative phosphorylation capacity of liver mitochondria. Digestive and Liver Disease, 2000, 32, 510-517.	0.4	53
39	Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. Journal of Hepatology, 2001, 35, 805-810.	1.8	53
40	ER- β expression in large bowel adenomas: Implications in colon carcinogenesis. Digestive and Liver Disease, 2008, 40, 260-266.	0.4	49
41	<i>Helicobacter pylori</i> therapy: Present and future. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 68.	0.6	49
42	Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association. World Journal of Gastroenterology, 2016, 22, 4802.	1.4	49
43	Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. European Journal of Clinical Investigation, 2013, 43, 1147-1155.	1.7	46
44	Proliferative activity of gastric epithelium in progressive stages of <i>Helicobacter pylori</i> infection. Digestive Diseases and Sciences, 1996, 41, 1132-1138.	1.1	45
45	Musosal tumour necrosis factor β in diverticular disease of the colon is overexpressed with disease severity. Colorectal Disease, 2012, 14, e258-63.	0.7	45
46	Quadruple Rescue erapy aer First and Second Line Failure for <i>Helicobacter pylori</i> Treatment: Comparison between Two Tetracycline-Based Regimens. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 367-370.	0.5	45
47	Optimizing proton pump inhibitors in <i>Helicobacter pylori</i> treatment: Old and new tricks to improve effectiveness. World Journal of Gastroenterology, 2019, 25, 5097-5104.	1.4	45
48	Molecular mechanisms of augmenter of liver regeneration as immunoregulator: its effect on interferon- β expression in rat liver. Digestive and Liver Disease, 2000, 32, 217-225.	0.4	43
49	Effect of Probiotic or Prebiotic Supplementation on Antibiotic Therapy in the Small Intestinal Bacterial Overgrowth: A Comparative Evaluation. Current Clinical Pharmacology, 2013, 8, 169-172.	0.2	42
50	Halitosis and <i>Helicobacter pylori</i> : a possible relationship. Digestive Diseases and Sciences, 1998, 43, 2733-2737.	1.1	41
51	Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis. Clinical Drug Investigation, 2006, 26, 673-676.	1.1	41
52	Oral Tacrolimus (FK 506) in Crohn's Disease Complicated by Fistulae of the Perineum. Journal of Clinical Gastroenterology, 2000, 30, 200-202.	1.1	41
53	Sequential treatment for <i>Helicobacter pylori</i> eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Alimentary Pharmacology and Therapeutics, 2003, 18, 641-646.	1.9	40
54	Quadruple therapy with lactoferrin for <i>Helicobacter pylori</i> eradication: A randomised, multicentre study. Digestive and Liver Disease, 2005, 37, 496-500.	0.4	39

#	ARTICLE	IF	CITATIONS
55	The "three-in-one" formulation of bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. <i>Helicobacter</i> , 2018, 23, e12502.	1.6	39
56	Effects of carbonated water on functional dyspepsia and constipation. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 991-999.	0.8	38
57	Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 16-28.	0.8	38
58	Change of point mutations in <i>Helicobacter pylori</i> rRNA associated with clarithromycin resistance in Italy. <i>Journal of Medical Microbiology</i> , 2014, 63, 453-457.	0.7	37
59	Noninvasive molecular analysis of <i>Helicobacter pylori</i> : Is it time for tailored first-line therapy?. <i>World Journal of Gastroenterology</i> , 2017, 23, 2453.	1.4	37
60	The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3531.	1.8	37
61	Treatment of a pancreatic endocrine tumor by ethanol injection guided by endoscopic ultrasound. <i>Endoscopy</i> , 2008, 40, E258-E259.	1.0	35
62	Cost-effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia. <i>Helicobacter</i> , 2010, 15, 221-226.	1.6	35
63	Furazolidone-based therapies for <i>Helicobacter pylori</i> infection: A pooled-data analysis. <i>Saudi Journal of Gastroenterology</i> , 2012, 18, 11.	0.5	35
64	Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled data analysis. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13028.	1.6	35
65	Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. <i>Digestive and Liver Disease</i> , 2007, 39, 811-817.	0.4	34
66	Primary clarithromycin resistance to <i>Helicobacter pylori</i> : Is this the main reason for triple therapy failure?. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2013, 4, 43.	0.5	34
67	<i>Helicobacter pylori</i> clarithromycin resistance detected by Etest and TaqMan real-time polymerase chain reaction: a comparative study. <i>Apmis</i> , 2012, 120, 712-717.	0.9	32
68	Phytoestrogens/insoluble fibers and colonic estrogen receptor β : Randomized, double-blind, placebo-controlled study. <i>World Journal of Gastroenterology</i> , 2013, 19, 4325.	1.4	32
69	Seronegative celiac disease: where is the specific setting?. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2015, 8, 110-6.	0.6	32
70	Modulation of rat hepatocyte proliferation by bile salts: In vitro and In vivo studies. <i>Hepatology</i> , 1996, 23, 1159-1166.	3.6	31
71	Effectiveness and pharmaceutical cost of sequential treatment for <i>Helicobacter pylori</i> in patients with non-ulcer dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 993-998.	1.9	31
72	Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1385-1390.	1.9	31

#	ARTICLE	IF	CITATIONS
73	Ulcerative colitis: From inflammation to cancer. Do estrogen receptors have a role?. World Journal of Gastroenterology, 2014, 20, 11496.	1.4	31
74	Seronegative Celiac Disease and Immunoglobulin Deficiency: Where to Look in the Submerged Iceberg?. Nutrients, 2015, 7, 7486-7504.	1.7	31
75	Clarithromycin resistance and Helicobacter pylori genotypes in Italy. Journal of Microbiology, 2006, 44, 660-4.	1.3	31
76	Evaluation of a commercial serological kit for detection of salivary immunoglobulin G to Helicobacter pylori. European Journal of Gastroenterology and Hepatology, 2000, 12, 1117-1120.	0.8	30
77	Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study. Digestive and Liver Disease, 2007, 39, 806-810.	0.4	30
78	Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: an alimentary survey. Scandinavian Journal of Gastroenterology, 2016, 51, 277-280.	0.6	30
79	New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study. World Journal of Gastroenterology, 2018, 24, 3021-3029.	1.4	30
80	The Puzzle of Coccoid Forms of Helicobacter pylori: Beyond Basic Science. Antibiotics, 2020, 9, 293.	1.5	30
81	Dietary Lifestyle and Colorectal Cancer Onset, Recurrence, and Survival: Myth or Reality?. Journal of Gastrointestinal Cancer, 2013, 44, 1-11.	0.6	29
82	Helicobacter pylori and Nonulcer Dyspepsia in Childhood: Clinical Pattern, Diagnostic Techniques, and Bacterial Strains. Journal of Pediatric Gastroenterology and Nutrition, 1999, 28, 296-300.	0.9	29
83	DNA sequences and proteic antigens of H. pylori in cholecystic bile and tissue of patients with gallstones. Alimentary Pharmacology and Therapeutics, 2005, 22, 715-720.	1.9	28
84	Lupus Nephritis Improvement After Anti-tumor Necrosis Factor Alpha Monoclonal Antibody (Infliximab) Treatment for Crohn's Disease: A Case Report. Immunopharmacology and Immunotoxicology, 2004, 26, 243-248.	1.1	27
85	Probiotic Multistrain Treatment May Eradicate Helicobacter pylori from the Stomach of Dyspeptics: A Placebo-Controlled Pilot Study. Inflammation and Allergy: Drug Targets, 2012, 11, 244-249.	1.8	27
86	Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. Scandinavian Journal of Gastroenterology, 2016, 51, 1429-1432.	0.6	27
87	Assessment of activity of Crohn's disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score. Radiologia Medica, 2013, 118, 181-195.	4.7	26
88	The Interaction Between Celiac Disease and Intestinal Microbiota. Journal of Clinical Gastroenterology, 2016, 50, S145-S147.	1.1	26
89	Helicobacter pylori infection: association with dietary habits and socioeconomic conditions. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 603-607.	0.7	26
90	Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for clarithromycin resistance in Helicobacter pylori. Digestive and Liver Disease, 2009, 41, 610-611.	0.4	25

#	ARTICLE	IF	CITATIONS
91	<i>Helicobacter pylori</i> and Nonmalignant Diseases. <i>Helicobacter</i> , 2014, 19, 27-31.	1.6	25
92	Inflammatory bowel disease, liver diseases and endothelial function. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 11-21.	0.6	25
93	Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up. <i>World Journal of Gastroenterology</i> , 2015, 21, 7545.	1.4	25
94	High rate of spontaneous viral clearance in a cohort of vertically infected hepatitis C virus infants: what lies behind?. <i>Journal of Hepatology</i> , 2001, 35, 687-688.	1.8	24
95	Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. <i>Hepatology</i> , 2003, 37, 880-886.	3.6	24
96	<i>Helicobacter pylori</i> Status and Symptom Assessment Two Years after Eradication in Pediatric Patients from a High Prevalence Area. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 312-318.	0.9	24
97	Complication of endoscopic ultrasound-guided celiac plexus neurolysis. <i>Endoscopy</i> , 2006, 38, 858-858.	1.0	24
98	Tumour Necrosis Factor Alpha in Segmental Colitis Associated with Diverticula. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1865-1868.	1.1	24
99	Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor- α in diverticular disease of the colon: a case-control study. <i>Neurogastroenterology and Motility</i> , 2012, 24, 836.	1.6	24
100	Differences in dietary habits between patients with inflammatory bowel disease in clinical remission and a healthy population. <i>Annals of Gastroenterology</i> , 2018, 31, 469-473.	0.4	24
101	Acute pancreatitis in elderly patients: A retrospective evaluation at hospital admission. <i>European Journal of Internal Medicine</i> , 2016, 30, 88-93.	1.0	23
102	Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model. <i>Carcinogenesis</i> , 2018, 39, 1274-1282.	1.3	23
103	Vonoprazan and <i>Helicobacter pylori</i> Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2019, 10, 316.	1.6	23
104	Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?. <i>Annals of Gastroenterology</i> , 2017, 30, 380-392.	0.4	23
105	<i>Helicobacter pylori</i> strains and histologically-related lesions affect the outcome of triple eradication therapy: a study from southern Italy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 421-428.	1.9	22
106	Treatment of a pancreatic endocrine tumor by ethanol injection (PEI) guided by endoscopic ultrasound. <i>Endoscopy</i> , 2008, 40, E83-E83.	1.0	22
107	Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 289-92.	0.7	22
108	Sequential vs. prolonged 14-day triple therapy for <i>Helicobacter pylori</i> eradication: the meta-analysis may be influenced by "geographical weighting"™. <i>International Journal of Clinical Practice</i> , 2015, 69, 1112-1120.	0.8	21

#	ARTICLE	IF	CITATIONS
109	Small Intestinal Contrast Ultrasonography-Based Scoring System. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 591-595.	1.1	20
110	The association between cardiac and gastrointestinal disorders. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 330-338.	0.6	20
111	Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 143-151.	0.6	20
112	Furazolidone therapy for <i>Helicobacter pylori</i> : Is it effective and safe?. <i>World Journal of Gastroenterology</i> , 2009, 15, 1914.	1.4	20
113	Argon Plasma Coagulation of Hemorrhagic Solitary Rectal Ulcer Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 392-394.	1.1	19
114	T Helper Lymphocyte and Mast Cell Immunohistochemical Pattern in Nonceliac Gluten Sensitivity. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	0.7	19
115	Effect of <i>Helicobacter pylori</i> infection on gastric emptying and gastrointestinal hormones in dyspeptic and healthy subjects. <i>Digestive Diseases and Sciences</i> , 2001, 46, 46-53.	1.1	18
116	Why do we still have <i>Helicobacter Pylori</i> in our Stomachs. <i>The Malaysian Journal of Medical Sciences</i> , 2015, 22, 70-75.	0.3	18
117	Catholic Bridging Efforts with China. <i>Religion, State and Society</i> , 2000, 28, 185-195.	0.3	17
118	Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. <i>Transplantation Proceedings</i> , 2001, 33, 2107-2109.	0.3	17
119	Infliximab single administration followed by acute liver injury. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 1089-1090.	0.9	17
120	<i>Helicobacter pylori</i> Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. <i>Antibiotics</i> , 2020, 9, 723.	1.5	17
121	Does Infliximab Short Infusion have a Beneficial Impact on the Quality of Life in Patients with Inflammatory Bowel Diseases? A Single Centre Prospective Evaluation. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 165-170.	0.5	17
122	May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis?. <i>World Journal of Gastroenterology</i> , 2016, 22, 8017.	1.4	17
123	Incidence and Risk Factors of Duodenal Ulcer. <i>Journal of Clinical Gastroenterology</i> , 1995, 20, 104-109.	1.1	16
124	Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. <i>World Journal of Gastroenterology</i> , 2020, 26, 7528-7537.	1.4	16
125	Demonstration of a Direct Stimulatory Effect of Bile Salts on Rat Colonic Epithelial Cell Proliferation. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 88-94.	0.6	15
126	Pattern of mucosal tumor necrosis factor- α expression in segmental colitis associated with diverticula suggests a truly autonomous clinical entity. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1315-1317.	0.9	15

#	ARTICLE	IF	CITATIONS
127	Helicobacter pylori antibiotic resistance and [13C]urea breath test values. Journal of Medical Microbiology, 2010, 59, 588-591.	0.7	15
128	Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 100.	0.5	15
129	Serrated Colorectal Lesions: An Up-to-Date Review from Histological Pattern to Molecular Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 4461.	1.8	15
130	Epithelial proliferation and ras p21 oncoprotein expression in rectal mucosa of patients with ulcerative colitis. Digestive Diseases and Sciences, 2001, 46, 1083-1087.	1.1	14
131	Mycophenolate mofetil in the treatment of autoimmune HCV-associated haematological disorders showing steroid resistance or dependence. Journal of Viral Hepatitis, 2003, 10, 390-393.	1.0	14
132	Segmental colitis associated with diverticula: A rare clinical entity and a new challenge for the gastroenterologist. Digestive and Liver Disease, 2009, 41, 794-797.	0.4	14
133	Mucosal assessment of tumor necrosis factor alpha levels on paraffined samples: a comparison between immunohistochemistry and real time polymerase chain reaction. Scandinavian Journal of Gastroenterology, 2010, 45, 1007-1008.	0.6	14
134	Metabolic syndrome and gastro-esophageal reflux: A link towards a growing interest in developed countries. World Journal of Gastrointestinal Pathophysiology, 2010, 1, 91.	0.5	14
135	Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. Journal of Gastrointestinal and Liver Diseases, 2011, 20, 235-9.	0.5	14
136	Estrogens, androgens, and EGF receptor expression in gastric carcinoma induced by N-methyl-N'-nitro-N-nitrosoguanidine. Digestive Diseases and Sciences, 1994, 39, 635-640.	1.1	13
137	Endothelial function and cardiovascular risk in patients with inflammatory bowel disease in remission phase. Scandinavian Journal of Gastroenterology, 2016, 51, 253-255.	0.6	13
138	The Spectrum of Small Intestinal Lesions in Patients with Unexplained Iron Deficiency Anemia Detected by Video Capsule Endoscopy. Medicina (Lithuania), 2019, 55, 59.	0.8	13
139	Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?. Current Drug Safety, 2014, 9, 196-204.	0.3	13
140	A New Semiquantitative Method of Quantifying Helicobacter pylori in Antigen Stools. Journal of Clinical Gastroenterology, 2002, 35, 375-378.	1.1	12
141	Tumor Necrosis Factor Alpha and Apoptosis in Helicobacter pylori Related Progressive Gastric Damage: A Possible Mechanism of Immune System Involvement in Epithelial Turnover Regulation. Immunopharmacology and Immunotoxicology, 2003, 25, 203-211.	1.1	12
142	The A2143G Point Mutation of Clarithromycin Resistance Affects Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2009, 43, 386.	1.1	12
143	Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis. Journal of Clinical Pathology, 2011, 64, 968-972.	1.0	12
144	The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma. Scandinavian Journal of Gastroenterology, 2015, 50, 1002-1010.	0.6	12

#	ARTICLE	IF	CITATIONS
145	Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 15-20.	0.9	12
146	Reversal of IgM deficiency following a gluten-free diet in seronegative celiac disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 17686.	1.4	12
147	Celiac disease and common variable immunodeficiency: a familial inheritance?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013, 22, 473.	0.5	12
148	Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor $\hat{\pm}$ in resected acute colonic diverticulitis. <i>Colorectal Disease</i> , 2014, 16, O98-103.	0.7	11
149	Regulation of apoptosis is impaired in atrophic gastritis associated with gastric cancer. <i>BMC Gastroenterology</i> , 2017, 17, 84.	0.8	11
150	From chronic liver disorders to hepatocellular carcinoma: Molecular and genetic pathways. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 259.	0.8	11
151	Sequential eradicating therapy: a treatment that does not discriminate <i>Helicobacter pylori</i> strains in patients with nonulcer dyspepsia?. <i>American Journal of Gastroenterology</i> , 2002, 97, 2686-2687.	0.2	10
152	The Use of Human Albumin for the Treatment of Ascites in Patients with Liver Cirrhosis: Item of Safety, Facts, Controversies and Perspectives. <i>Current Drug Safety</i> , 2011, 6, 267-274.	0.3	10
153	Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 373-377.	0.7	10
154	Predictivity of Autoimmune Stigmata for Gluten Sensitivity in Subjects with Microscopic Enteritis: A Retrospective Study. <i>Nutrients</i> , 2018, 10, 2001.	1.7	10
155	Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1138-1145.	1.9	10
156	Detection of <i>Helicobacter pylori</i> DNA sequences in gastric biopsy samples to refine the diagnosis and therapy. <i>Journal of Medical Microbiology</i> , 2015, 64, 788-789.	0.7	10
157	Pathological and Clinical Correlation between Celiac Disease and <i>Helicobacter Pylori</i> Infection; a Review of Controversial Reports. <i>Middle East Journal of Digestive Diseases</i> , 2016, 8, 85-92.	0.2	10
158	Silymarin, boswellic acid and curcumin enriched dietetic formulation reduces the growth of inherited intestinal polyps in an animal model. <i>World Journal of Gastroenterology</i> , 2020, 26, 1601-1612.	1.4	10
159	Acid exposure and altered acid clearance in GERD patients treated for <i>Helicobacter pylori</i> infection. <i>Digestive and Liver Disease</i> , 2003, 35, 151-156.	0.4	9
160	<i>Helicobacter pylori</i> vacA Arrangement and Related Diseases: A Retrospective Study Over a Period of 15 Years. <i>Digestive Diseases and Sciences</i> , 2009, 54, 97-102.	1.1	9
161	Tumour necrosis factor-alpha expression in segmental colitis associated with diverticulosis is related to the severity of the endoscopic damage. <i>Digestive and Liver Disease</i> , 2011, 43, 374-379.	0.4	9
162	Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study. <i>Pathogens</i> , 2020, 9, 870.	1.2	9

#	ARTICLE	IF	CITATIONS
163	Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages. Saudi Journal of Gastroenterology, 2015, 21, 379.	0.5	9
164	Nonsense variant of <i>ATP8B1</i> gene in heterozygosis and benign recurrent intrahepatic cholestasis: A case report and review of literature. World Journal of Hepatology, 2020, 12, 64-71.	0.8	9
165	Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives. Current Oncology, 2021, 28, 4256-4263.	0.9	9
166	Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer. Gastroenterology and Hepatology From Bed To Bench, 2018, 11, 203-208.	0.6	9
167	Gastric mucosa alterations in first-degree relatives of gastric cancer patients. Anticancer Research, 2005, 25, 2567-72.	0.5	9
168	Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?. American Journal of Gastroenterology, 2002, 97, 2686-2687.	0.2	8
169	Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 554-560.	1.4	8
170	Estrogen receptors expression in long-lasting ulcerative pancolitis with and without dysplasia: A preliminary report. Scandinavian Journal of Gastroenterology, 2012, 47, 1253-1254.	0.6	8
171	Chronic diverticulitis and Crohn's disease share the same expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor- α . Journal of Clinical Pathology, 2014, 67, 844-846.	1.0	8
172	<i>Helicobacter pylori</i> , liver cirrhosis, and portal hypertension: an updated appraisal. Immunopharmacology and Immunotoxicology, 2016, 38, 408-413.	1.1	8
173	Facilitating self-directed learning (SDL) and satisfaction with SDL among pre-university students. Educational Studies, 2017, 43, 584-599.	1.4	8
174	The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 4549.	1.2	8
175	Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn's Disease. Immunopharmacology and Immunotoxicology, 2006, 28, 185-195.	1.1	7
176	Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. Cell Death and Disease, 2017, 8, e3040-e3040.	2.7	7
177	Mucosal Expression of Basic Fibroblastic Growth Factor, Syndecan 1 and Tumor Necrosis Factor- α in Crohn's Disease in Deep Remission under Treatment with Anti-TNF α Antibodies. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 261-265.	0.5	7
178	Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?. World Journal of Gastroenterology, 2016, 22, 3202.	1.4	7
179	Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis. World Journal of Gastrointestinal Pathophysiology, 2013, 4, 53.	0.5	7
180	Sequential therapy for Helicobacter pylori: an aberrant therapy ready for general use. Digestive and Liver Disease, 2004, 36, 852-853.	0.4	6

#	ARTICLE	IF	CITATIONS
181	Symptoms and Pathophysiological Correlations in Patients with Constipation and Functional Dyspepsia. <i>Digestion</i> , 2005, 71, 225-230.	1.2	6
182	Differential Immunohistochemical Expression of Syndecan-1 and Tumor Necrosis Factor Alpha in Colonic Mucosa of Patients with Crohn's Disease. <i>Immunopharmacology and Immunotoxicology</i> , 2006, 28, 185-195.	1.1	6
183	The source of <i>Helicobacter pylori</i> infection in the neonatal period. <i>Journal of Perinatal Medicine</i> , 2009, 37, 288-292.	0.6	6
184	Is Furazolidone Therapy for <i>Helicobacter pylori</i> Effective and Safe?. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2298-2299.	1.1	6
185	Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?. <i>Scientific World Journal</i> , The, 2014, 2014, 1-6.	0.8	6
186	Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for <i>Helicobacter pylori</i> eradication: how should rifabutin be managed in rescue regimens?. <i>United European Gastroenterology Journal</i> , 2016, 4, 474-475.	1.6	6
187	Liver involvement in inflammatory bowel disease: What should the clinician know?. <i>World Journal of Hepatology</i> , 2021, 13, 1534-1551.	0.8	6
188	Gastro-oesophageal reflux disease and lactose malabsorption: Casual comorbidity or neglected association?. <i>Digestive and Liver Disease</i> , 2006, 38, 437-438.	0.4	5
189	Letter: <i>Helicobacter</i> -negative gastritis - a distinct condition?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 597-598.	1.9	5
190	Letter: could sequential therapy extended to 14 days replace prolonged triple regimens for <i>Helicobacter pylori</i> treatment?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 844-845.	1.9	5
191	Might <i>Helicobacter pylori</i> play a role in allergic or cross-reaction related disorders?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 643-646.	1.4	5
192	<i>Helicobacter pylori</i> Antibiotic Resistance: Stewardship, Tailored Therapies, and Future Perspectives. <i>Gastroenterology</i> , 2021, 161, 1071-1072.	0.6	5
193	Intraepithelial lymphocytes: bystanders or causative factors in functional gastrointestinal disorders?. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1620-1621.	4.8	5
194	Serologic diagnosis of celiac disease: May it be suitable for adults?. <i>World Journal of Gastroenterology</i> , 2021, 27, 7233-7239.	1.4	5
195	Gastroenterology: Video capsule endoscopy disclosure of unprecedented therapeutic effect of Eviendep on small bowel polyposis in Lynch syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 801-801.	1.4	4
196	Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture. <i>Current Drug Safety</i> , 2020, 15, 65-68.	0.3	4
197	Tumor Necrosis Factor Alpha in Ulcerative Colitis and Diverticular Disease Associated Colitis. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2007, 7, 187-194.	0.6	4
198	Liver fibrosis in primary intestinal lymphangiectasia: An undervalued topic. <i>World Journal of Hepatology</i> , 2014, 6, 685.	0.8	4

#	ARTICLE	IF	CITATIONS
199	Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions. <i>World Journal of Gastroenterology</i> , 2020, 26, 3834-3850.	1.4	4
200	Empiric "Three-in-One" Bismuth Quadruple Therapy for Second-Line Helicobacter pylori Eradication: An Intervention Study in Southern Italy. <i>Antibiotics</i> , 2022, 11, 78.	1.5	4
201	Second harmonic imaging improves trans-abdominal ultrasound detection of biliary sludge in "idiopathic" pancreatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 473-477.	1.9	3
202	A case of adverse reaction potentially related to a microbubble contrast agent for ultrasonography. <i>European Journal of Radiology Extra</i> , 2004, 52, 25-26.	0.1	3
203	Gastric epithelial cell proliferation and ras oncogene p21 expression in first-degree relatives of gastric cancer patients: a case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 921-926.	0.8	3
204	Endoscopic ultrasound-guided ethanol lavage of a pancreatic fluid collection. <i>Endoscopy</i> , 2006, 38, 951-951.	1.0	3
205	Helicobacter pylori clarithromycin resistance assessment: are gastric antral biopsies sufficient?. <i>Gastroenterology Insights</i> , 2012, 4, 2.	0.7	3
206	Alimentary disorders in young females with irritable bowel syndrome or ulcerative procto-sigmoiditis: A preliminary report. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e112-e113.	0.6	3
207	Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. <i>Diagnostics</i> , 2020, 10, 213.	1.3	3
208	Quinolone-based first, second and third-line therapies for Helicobacter pylori. <i>World Journal of Pharmacology</i> , 2015, 4, 274.	1.3	3
209	A prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter Pylori infection: A further confirmation of "Geographic Weight". <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 77.	0.5	3
210	Small Bowel Metastatic Melanoma: An Emblematic "Coal-Black" Appearance at Videocapsule Endoscopy. <i>Medicina (Lithuania)</i> , 2021, 57, 1313.	0.8	3
211	Endoscopic ultrasound localization of a solitary insulinoma of pancreatic tail misdiagnosed as epilepsy: case report. <i>Abdominal Imaging</i> , 2003, 28, 859-61.	2.0	2
212	Ileal metastasis from thoracic melanoma disclosed by video capsule endoscopy: an unusual but not extraordinary source of obscure bleeding. <i>Endoscopy</i> , 2007, 39, E109-E109.	1.0	2
213	Pseudotumoural lesion of the abdominal wall due to a fishbone migration. <i>Digestive and Liver Disease</i> , 2007, 39, 368.	0.4	2
214	Helicobacter pylori Detection by Stool Antigen Test in the Perinatal Period: An Inadequate Approach to Establish Maternal Transmission. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2008, 47, 673-674.	0.9	2
215	Letter: tumour necrosis factor alpha blocker switching - a not so simple pharmacokinetic. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1302-1302.	1.9	2
216	Persistence of endoscopic rectal inflammation in UC treated with infliximab is not linked to ineffective TNF α downregulation. <i>Gut</i> , 2016, 65, 539-540.	6.1	2

#	ARTICLE	IF	CITATIONS
217	Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C. <i>Diagnostics</i> , 2020, 10, 1037.	1.3	2
218	Second-line treatment for <i>Helicobacter pylori</i> eradication after sequential therapy failure: a pilot study. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 251-254.	0.2	2
219	Role of concomitant therapy for <i>Helicobacter pylori</i> eradication: A technical note. <i>World Journal of Gastroenterology</i> , 2016, 22, 8638.	1.4	2
220	May Antitransglutaminase Levels Predict Severity of Duodenal Lesions in Adults with Celiac Disease?. <i>Medicina (Lithuania)</i> , 2021, 57, 1212.	0.8	2
221	Immunohistostaining of hepatitis C virus non-structural protein 4 in ependymocytes of uninfected mice: An antigenic mimicry?. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 992-994.	0.6	1
222	<i>Helicobacter heilmannii</i> infection of the antrum and duodenal bulb. <i>Clinical Microbiology Newsletter</i> , 2006, 28, 37-40.	0.4	1
223	Immunosuppressant supplementation to infliximab in Crohn's disease with extraintestinal involvement: A benefit in the long term?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1463-1464.	0.9	1
224	A juvenile, misdiagnosed case of Whipple's disease. <i>Rheumatology International</i> , 2009, 30, 143-144.	1.5	1
225	Letter: portal vein obstruction – which subset of patients could benefit the most?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 909-909.	1.9	1
226	Recurrent Overt Gastrointestinal Bleeding from Ulcerated Gastric Elastofibroma: Unprecedented Presentation of a Rare Condition. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1074-1076.	0.6	1
227	Familial adenomatous polyposis small bowel surveillance: could indicators for video-capsule endoscopy be ascertained?. <i>Minerva Gastroenterologica E Dietologica</i> , 2016, 62, 272-3.	2.2	1
228	Cyclic Nucleotides in Ascites from Ovarian Carcinoma. <i>Hormone and Metabolic Research</i> , 1985, 17, 617-618.	0.7	0
229	Ultrasonographic contrast medium improves the diagnostic accuracy of ultrasound-guided fine-needle aspiration. <i>Endoscopy</i> , 2008, 40, 540-541.	1.0	0
230	Hepatic loss in a young patient: a very "cold case". <i>Internal and Emergency Medicine</i> , 2012, 7, 49-52.	1.0	0
231	Comment on "Outer Membrane Protein 18 (Hp1125) Is Involved in Persistent Colonization by Evading Interferon- γ Signaling". <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	0
232	Transjugular intrahepatic portosystemic shunt for a patient with chylothorax in cryptogenic/metabolic cirrhosis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 303-304.	0.6	0
233	Human Leukocyte Antigen (HLA) Haplotype Does Not Influence the Inflammatory Pattern of Duodenal Lymphocytosis Linked to Irritable Bowel Syndrome. <i>Medicina (Lithuania)</i> , 2020, 56, 660.	0.8	0
234	Does <i>Helicobacter pylori</i> Always Represent a Peaceful Host of Barrett's Esophagus?. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 424-425.	1.1	0

#	ARTICLE	IF	CITATIONS
235	A Mysterious Case of Gastroparesis: Could the Secret be Found in a Drink?. <i>Inflammation and Allergy: Drug Targets</i> , 2013, 12, 187-189.	1.8	0
236	A Prospective, Randomized Comparative Study of Respiratory and Hemodynamic Monitoring during Colonoscopy using Remifentanyl Versus Propofol/Fentanyl. <i>Journal of Anesthesia & Clinical Research</i> , 2014, 05, .	0.1	0
237	Sequential Therapy For Helicobacter pylori in Elderly Patients: Effectiveness, Safety and Predictors of Success. <i>Letters in Drug Design and Discovery</i> , 2017, 14, 500-505.	0.4	0
238	Epstein-Barr Virus-Related Hyperacute Hepatitis: May Intravenous Steroids be an Effective Approach?. <i>Anti-Infective Agents</i> , 2017, 15, 15-19.	0.1	0
239	Tumor necrosis alpha serum levels parallels isolated hypertransaminasemia in the third trimester of pregnancy. <i>Annals of Hepatology</i> , 2010, 9, 211-2.	0.6	0